ODG by MCG has adopted updates to its ODG Drug Formulary, which includes U.S. Food and Drug Administration (FDA) approved drugs listed by generic and/or brand names that are commonly prescribed for workplace injuries. All the updates are effective October 2, 2026.
Several states, including Indiana, Montana, and Texas, have adopted the ODG formulary for use in their workers’ compensation systems. These states, to varying degrees, require some type of prior authorization for medications listed as “N” status on the ODG formulary and, in some cases, for medications not listed on the ODG formulary.
MyMatrixx by Evernorth will make the following changes to our formularies in accordance with the ODG updates and deadline.
If you have questions on these changes and how they will impact your program, please contact your MyMatrixx account team.
New Entries to Appendix A ODG Formulary
| Medication | Use | ODG Status |
|---|---|---|
| Ibuprofen 300 mg tablet | Non-steroidal anti-inflammatory drug (NSAID) | N drug |
| Concerta®, Methylin® ER, Ritalin® (methylphenidate) | Stimulant | N drug |
| Please note: Ibuprofen 300 mg was previously excluded from the ibuprofen Y-drug list and is now specifically listed as an N-drug. Other ibuprofen options will remain as Y drugs. | ||
About ODG
ODG by MCG offers medical treatment and return-to-work solutions used to support the management of workers’ compensation, disability, and auto liability claim outcomes through evidence-based, data-driven decision support.
MyMatrixx Actions
MyMatrixx maintains ODG-based formularies and will update them in accordance with the above changes. For any changes, please reach out to your MyMatrixx account team.